Locally Advanced Pancreatic Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Locally Advanced Pancreatic Cancer Market Outlook

Thelansis’s “Locally Advanced Pancreatic Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Locally Advanced Pancreatic Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Locally Advanced Pancreatic Cancer Overview

Pancreatic adenocarcinoma is a highly aggressive form of cancer that originates from the cells lining the pancreatic ducts. Most cases of pancreatic cancer are classified as adenocarcinomas. At the time of diagnosis, the distribution of pancreatic cancer patients is approximately as follows: 20% with resectable tumors, 30% with locally advanced tumors, and 50% with metastatic disease. Locally advanced pancreatic cancer (LAPC) refers to a subgroup of patients who have pancreatic tumors that are deemed unresectable but have not yet spread to distant sites. These tumors exhibit certain characteristics that make them unsuitable for surgical removal, such as encasement of the superior mesenteric artery or coeliac axis of more than 180 degrees, unreconstructable superior mesenteric vein/portal vein occlusion, aortic involvement, or nodal involvement beyond the field of resection. The prognosis for LAPC patients falls between that of resectable and metastatic patients, with a median overall survival ranging from 5 to 11 months. The exact causes of the genetic and molecular changes leading to pancreatic cancer are not fully understood. However, certain risk factors have been identified that can increase the likelihood of developing the disease. These risk factors include smoking, inherited gene mutations (such as BRCA2 and PALB2 mutations), chronic pancreatitis, obesity, diabetes, and a family history of pancreatic cancer. In the treatment of stage III tumors, palliative FOLFIRINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin) is currently considered the gold standard. Surgical resection remains the only treatment option with the potential for long-term survival and cure in pancreatic cancer. However, surgical intervention is often limited to a small percentage of patients due to the advanced stage at which pancreatic cancer is typically diagnosed.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: